Market Place
Sourcing Support
Former Amryt Pharma Leadership Team join Poolbeg
09 Nov 2023 //
ACCESSWIRE
High Court of Justice of England and Wales Sanctions Scheme of Arrangement
03 Apr 2023 //
GLOBENEWSWIRE
Amryt Shareholders approve acquisition of Amryt Pharma by Chiesi Farmaceutici
22 Mar 2023 //
GLOBENEWSWIRE
Amryt Publishes Announces Shareholder Meetings to Vote On Chiesi Acquisition
16 Feb 2023 //
GLOBENEWSWIRE
After Amryt buy, Chiesi names Baxter vet Accogli its new CEO
30 Jan 2023 //
FIERCE PHARMA
Chiesi gets jump-start on JPM buzz with $1.48B Amryt buyout
09 Jan 2023 //
FIERCE PHARMA
Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc
08 Jan 2023 //
GLOBENEWSWIRE
Amryt Announces Positive Top Line Results from Ph3 Pediatric Trial of Lomitapide
05 Jan 2023 //
GLOBENEWSWIRE
Amryt Pharmaceuticals`s Mycapssa (octreotide) Receives Approval in Europe
22 Dec 2022 //
EMA
COMP Adopts Positive Opinion on Orphan Designation for Mycapssa
19 Dec 2022 //
GLOBENEWSWIRE
Amryt Announces New Patent for Mycapssa®
30 Nov 2022 //
GLOBENEWSWIRE
Amryt Supports Global EB Awareness Week 2022
24 Oct 2022 //
GLOBENEWSWIRE
Amryt to Report Q3 2022 Results on November 3, 2022
19 Oct 2022 //
GLOBENEWSWIRE
Amryt Receives Reimbursement Approval from the Dutch Ministry for Myalepta
17 Oct 2022 //
GLOBENEWSWIRE
CHMP adopts positive opinion for Mycapssa® for the treatment of Acromegaly
16 Sep 2022 //
GLOBENEWSWIRE
Amryt Announces New Patent for Mycapssa®
13 Sep 2022 //
GLOBENEWSWIRE
Amryt to Present Data from MPOWERED Phase 3 Trial of Mycapssa® (
07 Sep 2022 //
GLOBENEWSWIRE
Amryt Receives ODD from FDA for Mycapssa for Carcinoid Syndrome
14 Jul 2022 //
GLOBENEWSWIRE
Amryt Presents New Analyses from EASE PIII Trial in Epidermolysis Bullosa
07 Jul 2022 //
GLOBENEWSWIRE
Amryt Pharma`s Filsuvez (birch bark extract) Receives Approval in the EMA
04 Jul 2022 //
FDA
Amryt Pharmaceutical`s Filsuvez Receives Approval in Europe
04 Jul 2022 //
EMA
Results of Annual General Meeting
01 Jul 2022 //
GLOBENEWSWIRE
Amryt Announces Appointment of Dr Tracy Cunningham as Chief Medical Officer
27 Jun 2022 //
GLOBENEWSWIRE
Amryt submits formal dispute resolution to FDA over rejected skin disease drug
25 Jun 2022 //
ENDPTS
Amryt to Present Data from PIII Trials Open Label Extension of Mycapssa
08 Jun 2022 //
GLOBENEWSWIRE
Posting of Annual Report and Notice of AGM
01 Jun 2022 //
GLOBENEWSWIRE
Amryt Announces Details of EMA Contingent Value Rights Payment
17 May 2022 //
GLOBENEWSWIRE
Amryt Announces New Patent for Mycapssa®
11 May 2022 //
GLOBENEWSWIRE
Amryt Reports Record Q1 2022 Results
04 May 2022 //
GLOBENEWSWIRE
CHMP adopts positive opinion for Filsuvez® for the treatment of Dystrophic
22 Apr 2022 //
GLOBENEWSWIRE
Amryt to Report Q1 2022 Results on May 4, 2022
14 Apr 2022 //
GLOBENEWSWIRE
Amryt Announces Positive Long-Term Safety and Efficacy Data for Mycapssa
13 Apr 2022 //
GLOBENEWSWIRE
Amryt Announces Positive Interim Analysis Data From EASE Phase 3 Trial in EB
26 Mar 2022 //
GLOBENEWSWIRE
Amryt says 22% growth in FY 2021 Revenues to $222.5M
09 Mar 2022 //
GLOBENEWSWIRE
Amryt says Successful Bioavailability Study for Mycapssa® (octreotide capsules)
08 Mar 2022 //
GLOBENEWSWIRE
U.S. FDA declines to approve Amryt`s topical gel for rare skin diseases
01 Mar 2022 //
REUTERS
Amryt Supports Rare Disease Day 2022
25 Feb 2022 //
GLOBENEWSWIRE
Amryt to Report FY and Q4 2021 Results on March 9, 2022
23 Feb 2022 //
GLOBENEWSWIRE
Amryt Completes $125 Million Non-Dilutive Debt Refinancing
22 Feb 2022 //
GLOBENEWSWIRE
Another delay at Amryt as EMA calls in experts to inform review
29 Jan 2022 //
FIERCEBIOTECH
Amryt Announces New Patents for Oleogel-S10
18 Jan 2022 //
GLOBENEWSWIRE
Amryt Announces Positive Long-Term Safety and Efficacy Data for Mycapssa
11 Jan 2022 //
GLOBENEWSWIRE
Amryt Provides Update on Regulatory Review Process for Oleogel-S10
23 Nov 2021 //
GLOBENEWSWIRE
Amryt Announces the Cancellation of Admission of its Ordinary Shares
22 Nov 2021 //
GLOBENEWSWIRE
Amryt Announces New Patents for Oleogel-S10 and Mycapssa®
19 Oct 2021 //
GLOBENEWSWIRE
Amryt Issues Ordinary Shares and Total Voting Rights
19 Aug 2021 //
GLOBENEWSWIRE
Amryt Virtual Capital Markets Event - September 13, 2021 – 1000-1200 EDT
09 Aug 2021 //
GLOBENEWSWIRE
Amryt Virtual Capital Markets Event - September 13, 2021 – 1000-1200 EDT
09 Aug 2021 //
GLOBENEWSWIRE
Amryt Reports Record Q2 2021 Results and Raises FY 2021 Guidance
06 Aug 2021 //
GLOBENEWSWIRE
Amryt Successfully Completes Acquisition of Chiasma
05 Aug 2021 //
GLOBENEWSWIRE
Amryt to Report Q2 2021 Results and Host Conference Call & Webcast on August 6
12 Jul 2021 //
GLOBENEWSWIRE
Publication of Circular to Amryt Shareholders in relation to Chiasma acquisition
28 Jun 2021 //
GLOBENEWSWIRE
Amryt Pharma Announces update on Proposed Acquisition of Chiasma, Inc.
15 Jun 2021 //
GLOBENEWSWIRE
FDA confirms NDA for Oleogel-S10 will not require an Advisory Committee Meeting
07 Jun 2021 //
GLOBENEWSWIRE
Amryt Pharma to Acquire Chiasma, to Further Strengthen Global Leadership
05 May 2021 //
GLOBENEWSWIRE
Amryt Announces Results from an Investigator Sponsored Study of Lomitapide
30 Mar 2021 //
GLOBENEWSWIRE
Amryt Pharma signs another distribution deal with Medison
08 Mar 2021 //
SHARECAST
Amryt and Medison Pharma Sign Multi-Regional Distribution Agreements
04 Feb 2021 //
GLOBENEWSWIRE
Amryt Group Receives Marketing Authorisation Approval for Lojuxta® in Brazil
09 Dec 2020 //
GLOBENEWSWIRE
